Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q4 FY26 results · Jan–Mar 2026
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,157.87 crore (up 9.7% from Q4 FY25) and net profit of ₹81.34 crore (down 45.6% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,157.87 | 1,055.55 | +9.7% | 1,159.59 | −0.1% |
| Other income | 35.30 | 17.55 | +101.2% | 34.33 | +2.8% |
| Total income | 1,193.17 | 1,073.09 | +11.2% | 1,193.91 | −0.1% |
| Profit before tax | 121.22 | 75.14 | +61.3% | 99.57 | +21.7% |
| Net profit for the period | 81.34 | 149.61 | −45.6% | 67.67 | +20.2% |
| Attributable to shareholders of the company | 84.61 | 147.62 | −42.7% | 66.32 | +27.6% |
| EPS, basic (₹) | 5.53 | 9.64 | not comparable | 4.33 | +27.7% |
| Net margin (%) | 7.0 | 14.2 | 5.8 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.37 | 328.75 | +2.9% | 368.61 | −8.2% |
| Other income | 27.73 | 32.05 | −13.5% | 29.60 | −6.3% |
| Total income | 366.10 | 360.80 | +1.5% | 398.21 | −8.1% |
| Profit before tax | 21.79 | 37.05 | −41.2% | 35.87 | −39.2% |
| Net profit for the period | 15.20 | 27.59 | −44.9% | 28.11 | −45.9% |
| EPS, basic (₹) | 0.99 | 1.80 | −45.0% | 1.84 | −46.2% |
| Net margin (%) | 4.5 | 8.4 | 7.6 |
Consolidated
- Filed with BSE
- 25 Jul 2026, 17:50 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jul 2026, 17:50 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE